IBDEI1TC ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32366,0)
 ;;=D86.86^^190^1953^39
 ;;^UTILITY(U,$J,358.3,32366,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32366,1,3,0)
 ;;=3^Sarcoid Arthropathy
 ;;^UTILITY(U,$J,358.3,32366,1,4,0)
 ;;=4^D86.86
 ;;^UTILITY(U,$J,358.3,32366,2)
 ;;=^5002451
 ;;^UTILITY(U,$J,358.3,32367,0)
 ;;=D86.87^^190^1953^43
 ;;^UTILITY(U,$J,358.3,32367,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32367,1,3,0)
 ;;=3^Sarcoid Myositis
 ;;^UTILITY(U,$J,358.3,32367,1,4,0)
 ;;=4^D86.87
 ;;^UTILITY(U,$J,358.3,32367,2)
 ;;=^5002452
 ;;^UTILITY(U,$J,358.3,32368,0)
 ;;=D86.3^^190^1953^49
 ;;^UTILITY(U,$J,358.3,32368,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32368,1,3,0)
 ;;=3^Sarcoidosis of Skin
 ;;^UTILITY(U,$J,358.3,32368,1,4,0)
 ;;=4^D86.3
 ;;^UTILITY(U,$J,358.3,32368,2)
 ;;=^5002445
 ;;^UTILITY(U,$J,358.3,32369,0)
 ;;=D86.81^^190^1953^41
 ;;^UTILITY(U,$J,358.3,32369,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32369,1,3,0)
 ;;=3^Sarcoid Meningitis
 ;;^UTILITY(U,$J,358.3,32369,1,4,0)
 ;;=4^D86.81
 ;;^UTILITY(U,$J,358.3,32369,2)
 ;;=^5002446
 ;;^UTILITY(U,$J,358.3,32370,0)
 ;;=D86.82^^190^1953^50
 ;;^UTILITY(U,$J,358.3,32370,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32370,1,3,0)
 ;;=3^Sarcoidosis,Multiple Cranial Nerve Palsies
 ;;^UTILITY(U,$J,358.3,32370,1,4,0)
 ;;=4^D86.82
 ;;^UTILITY(U,$J,358.3,32370,2)
 ;;=^5002447
 ;;^UTILITY(U,$J,358.3,32371,0)
 ;;=D86.84^^190^1953^44
 ;;^UTILITY(U,$J,358.3,32371,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32371,1,3,0)
 ;;=3^Sarcoid Pyelonephritis
 ;;^UTILITY(U,$J,358.3,32371,1,4,0)
 ;;=4^D86.84
 ;;^UTILITY(U,$J,358.3,32371,2)
 ;;=^5002449
 ;;^UTILITY(U,$J,358.3,32372,0)
 ;;=D86.85^^190^1953^42
 ;;^UTILITY(U,$J,358.3,32372,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32372,1,3,0)
 ;;=3^Sarcoid Myocarditis
 ;;^UTILITY(U,$J,358.3,32372,1,4,0)
 ;;=4^D86.85
 ;;^UTILITY(U,$J,358.3,32372,2)
 ;;=^5002450
 ;;^UTILITY(U,$J,358.3,32373,0)
 ;;=D86.83^^190^1953^40
 ;;^UTILITY(U,$J,358.3,32373,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32373,1,3,0)
 ;;=3^Sarcoid Iridocyclitis
 ;;^UTILITY(U,$J,358.3,32373,1,4,0)
 ;;=4^D86.83
 ;;^UTILITY(U,$J,358.3,32373,2)
 ;;=^5002448
 ;;^UTILITY(U,$J,358.3,32374,0)
 ;;=D84.1^^190^1953^17
 ;;^UTILITY(U,$J,358.3,32374,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32374,1,3,0)
 ;;=3^Defects in Complement System
 ;;^UTILITY(U,$J,358.3,32374,1,4,0)
 ;;=4^D84.1
 ;;^UTILITY(U,$J,358.3,32374,2)
 ;;=^5002439
 ;;^UTILITY(U,$J,358.3,32375,0)
 ;;=D81.810^^190^1953^7
 ;;^UTILITY(U,$J,358.3,32375,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32375,1,3,0)
 ;;=3^Biotinidase Deficiency
 ;;^UTILITY(U,$J,358.3,32375,1,4,0)
 ;;=4^D81.810
 ;;^UTILITY(U,$J,358.3,32375,2)
 ;;=^5002422
 ;;^UTILITY(U,$J,358.3,32376,0)
 ;;=E88.01^^190^1953^4
 ;;^UTILITY(U,$J,358.3,32376,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32376,1,3,0)
 ;;=3^Apha-1 Antitrypsin Deficiency
 ;;^UTILITY(U,$J,358.3,32376,1,4,0)
 ;;=4^E88.01
 ;;^UTILITY(U,$J,358.3,32376,2)
 ;;=^331442
 ;;^UTILITY(U,$J,358.3,32377,0)
 ;;=J09.X1^^190^1953^26
 ;;^UTILITY(U,$J,358.3,32377,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32377,1,3,0)
 ;;=3^Influenza d/t Indent Novel Influenza A Virus w/ Pneumonia
 ;;^UTILITY(U,$J,358.3,32377,1,4,0)
 ;;=4^J09.X1
 ;;^UTILITY(U,$J,358.3,32377,2)
 ;;=^5008144
 ;;^UTILITY(U,$J,358.3,32378,0)
 ;;=J09.X2^^190^1953^27
 ;;^UTILITY(U,$J,358.3,32378,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32378,1,3,0)
 ;;=3^Influenza d/t Indent Novel Influenza A Virus w/ Resp Manifest
 ;;^UTILITY(U,$J,358.3,32378,1,4,0)
 ;;=4^J09.X2
 ;;^UTILITY(U,$J,358.3,32378,2)
 ;;=^5008145
 ;;^UTILITY(U,$J,358.3,32379,0)
 ;;=J09.X3^^190^1953^28
